BioGaia AB Class B BIOG B

Morningstar Rating

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BIOG B is trading at a 664% premium.
Price
SEK 113.17
Fair Value
SEK 52.35
Uncertainty
Very High
1-Star Price
SEK 321.32
5-Star Price
SEK 75.99
Economic Moat
Dylrsp
Capital Allocation

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
29.45
Price/Sales
8.36
Dividend Yield (Trailing)
1.68%
Dividend Yield (Forward)
1.68%
Total Yield
1.68%

Company Profile

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
220

Comparables

Valuation

Metric
BIOG B
PROB
605116
Price/Earnings (Normalized)
29.45204.8626.55
Price/Book Value
7.272.094.15
Price/Sales
8.364.616.09
Price/Cash Flow
24.4533.8918.00
Price/Earnings
BIOG B
PROB
605116

Financial Strength

Metric
BIOG B
PROB
605116
Quick Ratio
4.584.511.29
Current Ratio
6.496.042.22
Interest Coverage
132.852.43163.49
Quick Ratio
BIOG B
PROB
605116

Profitability

Metric
BIOG B
PROB
605116
Return on Assets (Normalized)
17.97%0.88%14.01%
Return on Equity (Normalized)
20.83%0.96%18.41%
Return on Invested Capital (Normalized)
18.84%0.48%16.29%
Return on Assets
BIOG B
PROB
605116

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
SptzmmbgdvRsdk$88.3 Bil
Merck KGaA ADR
MKKGY
ZdgtzkjyphFshstcf$77.4 Bil
Haleon PLC ADR
HLN
WwlwyxxVklh$47.3 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
JwzhbfzVshww$19.0 Bil
Viatris Inc
VTRS
NdzjbxwhVtns$13.9 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
LnvdcyxjFmwx$13.4 Bil
Catalent Inc
CTLT
TzwrzfgcNntdsj$10.9 Bil
Prestige Consumer Healthcare Inc
PBH
CfgdxylnNdwvp$3.5 Bil
Perrigo Co PLC
PRGO
RclyncnJjxg$3.5 Bil
Green Thumb Industries Inc
GTBIF
KpklrlvrcZwv$2.5 Bil

Sponsor Center